Utama › Kanser Paru-paru › Texas › San Antonio
Kajian klinikal Kanser Paru-paru di San Antonio, TX
26 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar San Antonio (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Audie L Murphy VA Hospital, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Texas San Antonio (UTSA), San Antonio
A Study of PHN-012 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- PHN-012-001 Site, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Mengambil pesertaFasa 2/3
- Local Institution - 0173, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Mengambil pesertaFasa 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Mengambil pesertaFasa 1/2
- START San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- START - San Antonio, San Antonio
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Mengambil pesertaFasa 1/2
- Avenzo Therapeutics Recruiting Site, San Antonio
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Mengambil pesertaFasa 1
- START San Antonio, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- START - San Antonio, San Antonio
IDOV-Immune for Advanced Solid Tumors
Mengambil pesertaFasa 1
- South Texas Accelerated Research Therapeutics, San Antonio
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Mengambil peserta
- Audie Murphy VA Medical Center, San Antonio
- Brooke Army Medical Center, San Antonio
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Mengambil pesertaFasa 1/2
- Mays Cancer Center / University of Texas, San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Mengambil pesertaFasa 1
- NEXT Oncology, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Mengambil pesertaFasa 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- START, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Mengambil pesertaFasa 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Next Oncology, San Antonio
A Study of ZW251 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- START San Antonio, San Antonio
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Mengambil pesertaKajian pemerhatian
- UT Health San Antonio, M.D. Anderson Cancer Center, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Mengambil pesertaFasa 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Mengambil pesertaFasa 1/2
- Next Oncology, San Antonio, San Antonio
Collection of Sputum and Labeling for Lung Cancer
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital, San Antonio
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di San Antonio
- Kanser Paru-paru Bukan Sel Kecil59 kajian
- Kanser Kolorektal46 kajian
- Kanser Payudara46 kajian
- Kanser Metastatik44 kajian
- Kanser (semua jenis)41 kajian
- Obesiti40 kajian
- Diabetes Jenis 237 kajian
- Berat Badan Berlebihan34 kajian
- Kanser Ovari31 kajian
- Kanser Pankreas31 kajian
- Kanser Prostat28 kajian
- Kanser Endometrium27 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.